Webcast Transcript
CDC Responds: Coping with Bioterrorism—The Role of the Laboratorian
(November 9, 2001)
(View the webcast on the University of North Carolina School of Public Health site.)
Segment 2 of 9
1
| 2 | 3
| 4 | 5 | 6 | 7 | 8 | 9
<< previous
| contents | next >>
Ms. Lisa Rayam:
As you’ve just heard from Dr. Koplan, the link between the
clinical laboratory community and public health laboratories is
an essential link in addressing bioterrorism. I’m Lisa Rayam, and
welcome to “CDC Responds: Coping with Bioterrorism—The Role of the Laboratorian,” which is the first
in a series of programs that will be coming to you live from the
CDC in Atlanta. The CDC is dedicated to keeping you, our audience,
aware of the latest laboratory guidelines and procedures for addressing
threats or actual events related to bioterrorism.
Now, before we continue, here are some important contact numbers
you’ll need if you have trouble receiving this program during our
broadcast. For technical assistance in the United States, please
call 800-728-8232. Our international technical assistance number
is 404-639-1289.
And now, let me introduce you to Dr. Fred Tenover, who, along with
our first panel of experts from CDC’s National Center for Infectious
Diseases, will provide an overview of laboratory issues for responding
to bioterrorism incidents, and a preparedness guidance for all laboratories.
Dr. Tenover, welcome, and please introduce your panelists.
Dr. Fred Tenover:
Thank you, Lisa. Today we are very pleased to have with
us Dr. Tanja Popovic, the chief of the epidemiologic investigations
laboratory at CDC; Mr. Richard Kellogg, the interagency liaison
and CDC Laboratory Response Network coordinator; and Dr. J. Michael
Miller, the chief of the epidemiology and laboratory branch. Our
objectives for the program today are: to describe the laboratory
tests used to diagnose the current cases of anthrax in the United
States; second of all, to describe the structure of the Laboratory
Response Network and the rationale for the Level A, B, C, and D
laboratories; and then finally, to define the testing performed
at the Level A through D laboratories, and the methods that are
appropriate for specimen referral.
1
| 2 | 3
| 4 | 5 | 6 | 7 | 8 | 9
<< previous
| contents | next >>
Page last modified November 20, 2002